We did selleck Seliciclib not perform repeat studies and therefore could not verify the accuracy of our findings. We would like to conduct the post hoc analysis of diet using the available data to further enhance the knowledge on this aspect. Subject flow was mostly from specialty endocrinology/diabetology centres from urban areas and may not completely represent the actual T2DM participants in India. Conclusion Data from the present cross-sectional study show that CHO constitutes 64.1% of total energy from diet in the T2DM group, which is higher than the recommended level.

There was clear non-adherence (self-reported) to dietary advice in the T2DM group. Our findings need to be confirmed in a larger epidemiological survey. Supplementary Material Author’s manuscript: Click here to view.(1.5M, pdf) Reviewer comments: Click here to view.(146K, pdf) Acknowledgments The authors thank Makrocare CRO for providing data management, statistical analysis and medical writing support. Footnotes Contributors: SRJ, RR and PVM were

involved in the study concept; study design; data collection and analysis; and manuscript writing, review and finalisation. AB, SB, SSB, MD, SG, SM, PRS, RS and SS were involved in data collection and analysis, as well as in reviewing the manuscript. SSJ was involved in the study design, data analysis related to dietary survey, development and validation of the dietary survey and review of the manuscript. Funding: Study sponsor (Bayer Zydus Pharma, India) was involved in the study concept; study centre selection, study design;

collection, analysis and interpretation of data; and in the decision to submit the article for publication. Makrocare was contracted by the sponsor for data management, statistical analysis and medical writing. Competing interests: SRJ: Author: Bayer Zydus Pharma; Speaker: Sanofi, Abbott, USV, Franco Indian, Ranbaxy, PHFI, MSD, Novartis, J & J, Roche Diagnostics, Novo Nordisk, Marico, Emcure; Consultant, Investigator: Bayer Zydus Pharma; Research Support: Bayer Zydus Pharma; AB: Research Grant: Bayer Zydus Pharma; SB: Investigator: Bayer Zydus Pharma; SSB: Investigator: Bayer Zydus Pharma; MD: Research Grant: Bayer Zydus Pharma; SG: Investigator: Bayer Zydus Pharma; SM: Investigator: Bayer Zydus Pharma; PRS: Advisor, Speaker, Investigator: Bayer Zydus Pharma; RS: Author, Investigator: Bayer Cilengitide Zydus Pharma; Advisor: Sanofi, Eli Lily; Advisor, Author: Nova Nordisk; Speaker: USV India, Alkem; SS: Investigator: Bayer Zydus Pharma; SSJ: Author, Consultant, Investigator: Emcure, Bayer Zydus Pharma; RTR & PVM: Author, Employee: Bayer Zydus Pharma, India. Bayer Zydus pharma markets acarbose in India. Ethics approval: The study was conducted in accordance with principles of Good Clinical Practice and was approved by the ethics committee.